Adicet BioACET
ACET
About: Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
Employees: 152
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
143% more call options, than puts
Call options by funds: $34K | Put options by funds: $14K
0% more funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 2 (+0) [Q1 2025]
2.37% less ownership
Funds ownership: 69.92% [Q4 2024] → 67.55% (-2.37%) [Q1 2025]
13% less funds holding
Funds holding: 64 [Q4 2024] → 56 (-8) [Q1 2025]
24% less capital invested
Capital invested by funds: $55.4M [Q4 2024] → $42M (-$13.4M) [Q1 2025]
41% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 22
67% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 12
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$7
833%
upside
Avg. target
$7
833%
upside
High target
$7
833%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Guggenheim Yatin Suneja | 833%upside $7 | Buy Reiterated | 21 Mar 2025 |
Financial journalist opinion
Neutral
Business Wire
3 weeks ago
Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare Conference
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference being held from June 3-5, 2025 in New York. Details of the event are as follows: Date: Wednesday, June 4, 2025 Time: 4:20.
Positive
Zacks Investment Research
1 month ago
Adicet Bio (ACET) Upgraded to Buy: Here's What You Should Know
Adicet Bio (ACET) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Neutral
Business Wire
1 month ago
Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the first quarter ended March 31, 2025. “We are approaching an exciting inflection point for our pipeline, with significant data milestones on the horizon,” said Chen Schor, President and Chief Executive Officer.
Neutral
Business Wire
1 month ago
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on April 30, 2025. Three individuals were hired by Adicet in April 2025. In the aggregate, Adicet granted new hires non-qualified stock options to purchase 206,800 shares of Adicet's common stock with an exercise price of $0.66 per.
Neutral
Business Wire
1 month ago
Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the 2025 Citizens JMP Life Sciences Conference being held from May 7-8, 2025 in New York. Details of the event are as follows: Date: Wednesday, May 7, 2025 Time: 1:3.
Neutral
Business Wire
1 month ago
Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the acceptance of an abstract for an oral presentation at the upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting taking place May 13-17, 2025, in New Orleans, LA. Details of the oral presentation are as follows: Title: ADI-270, an Armo.
Neutral
Business Wire
1 month ago
Adicet Bio Appoints Michael Grissinger to the Board of Directors
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the appointment of Michael Grissinger to its Board of Directors. Mr. Grissinger brings more than four decades of experience in business development, strategy, and M&A leadership roles at global pharmaceutical companies. “We are honored to welcome Michael t.
Neutral
Business Wire
2 months ago
Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on March 31, 2025. Two individuals were hired by Adicet in March 2025. In the aggregate, Adicet granted new hires non-qualified stock options to purchase 38,600 shares of Adicet's common stock with an exercise price of $0.76 per sh.
Neutral
Business Wire
2 months ago
Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a panel at the Canaccord Genuity Horizons in Oncology Virtual Conference being held April 7, 2025. Details of the event are as follows: Panel: “CAR T Approaches in the Autoimmune Space.
Neutral
Business Wire
3 months ago
Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the fourth quarter and year ended December 31, 2024. “In 2025 we plan to continue advancing our gamma delta 1 CAR T cell therapy programs, achieving key milestones and reporting preliminary data in autoimmune and.
Charts implemented using Lightweight Charts™